Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Davidson, Antonia M.
Funding for this research was provided by:
Novartis Pharma AG, Basel, Switzerland
Text and Data Mining valid from 2018-08-13